PHI with Ulcerative rectosigmoiditis
How does this condition affect your private health insurance?
Ulcerative Rektosigmoiditis is a form of ulcerative colitis, a chronic inflammatory bowel disease (IBD) affecting the rectum and sigmoid colon. It is characterized by inflammation and ulcers in these specific segments of the large intestine. Symptoms often include bloody diarrhea, tenesmus, urgency, and abdominal pain. The inflammation is typically superficial, confined to the innermost lining of the bowel. While it can cause significant discomfort and impact quality of life, it is generally considered a milder form of ulcerative colitis. Diagnosis involves colonoscopy with biopsies. Treatment aims to reduce inflammation, alleviate symptoms, and achieve remission, often involving oral or topical anti-inflammatory medications.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months for an untreated flare
Duration of Illness (Lifetime)
Chronic disease with periods of remission and relapse
Cost of Treatment (Initial)
Moderate (e.g., $1,000 - $5,000 USD for initial diagnostics and treatment)
Cost of Treatment (Lifetime)
High (e.g., $50,000 - $200,000+ USD over a lifetime, depending on disease course and medication)
Mortality Rate
Very low with proper medical management; complications can rarely be life-threatening
Risk of Secondary Damages
Moderate (e.g., anemia, increased risk of colorectal cancer over many years, extra-intestinal manifestations, rarely toxic megacolon or strictures)
Probability of Full Recovery
Low (not curable, but long-term remission is often achievable with treatment)
Underlying Disease Risk
Low to moderate (e.g., other autoimmune conditions, but not a direct causal link at onset)